Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Madrigal Pharmaceuticals Inc (MDGL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,214,805
  • Shares Outstanding, K 15,417
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,810 K
  • 60-Month Beta 1.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.91
  • Number of Estimates 6
  • High Estimate -0.75
  • Low Estimate -1.04
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -102.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
118.26 +21.63%
on 02/20/19
148.18 -2.93%
on 03/05/19
+9.59 (+7.14%)
since 02/19/19
3-Month
91.56 +57.10%
on 12/24/18
148.18 -2.93%
on 03/05/19
+40.40 (+39.06%)
since 12/19/18
52-Week
91.56 +57.10%
on 12/24/18
325.98 -55.87%
on 06/06/18
+22.65 (+18.69%)
since 03/19/18

Most Recent Stories

More News
Intercept (ICPT) Up on Q4 Revenue Beat, NASH Study in Focus

Intercept's (ICPT) Q4 revenues top estimates owing to strong Ocaliva sales, driven by sales force expansion and growth in its foreign geographies.

MRK : 81.91 (+0.69%)
MDGL : 143.84 (+0.13%)
GILD : 65.49 (+0.72%)
ICPT : 111.97 (-1.40%)
Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2018 financial results and highlights:

MDGL : 143.84 (+0.13%)
Intercept Reports Positive Top-Line Data for NASH, Shares Up

Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.

MRK : 81.91 (+0.69%)
MDGL : 143.84 (+0.13%)
GILD : 65.49 (+0.72%)
ICPT : 111.97 (-1.40%)
Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails

Gilead (GILD) suffers a setback as its phase III study on pipeline candidate, selonsertib, in patients with compensated cirrhosis (F4) due to NASH fails to meet goal.

VKTX : 8.62 (+1.41%)
MDGL : 143.84 (+0.13%)
GILD : 65.49 (+0.72%)
ICPT : 111.97 (-1.40%)
Notable Friday Option Activity: MDGL, WRLD, MDR

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Madrigal Pharmaceuticals Inc , where a total of 1,705 contracts have traded so far, representing...

MDGL : 143.84 (+0.13%)
Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018

Intercept (ICPT) outperforms the broader market in 2018 as lead drug Ocaliva recovers, following the company's efforts to increase awareness about the updated label.

MDGL : 143.84 (+0.13%)
GILD : 65.49 (+0.72%)
ICPT : 111.97 (-1.40%)
GLMD : 8.88 (+1.83%)
Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CASI Pharmaceuticals, Inc....

DERM : 14.13 (+12.05%)
MDGL : 143.84 (+0.13%)
ESGR : 171.17 (-1.27%)
CASI : 3.31 (+0.30%)
KALU : 104.18 (-0.39%)
BKNG : 1,764.03 (+0.44%)
Insiders Pile Into Holdings of FTXH ETF

A look at the weighted underlying holdings of the First Trust Nasdaq Pharmaceuticals ETF (FTXH) shows an impressive 20.8% of holdings on a weighted basis have experienced insider buying within the past...

MDGL : 143.84 (+0.13%)
Phase 2 Results for Madrigal's MGL-3196 in Non-Alcoholic Steatohepatitis (NASH) Presented during Presidential Plenary Clinical Session of The Liver Meeting(R) 2018

-- Statistically significantly more NASH resolution in MGL-3196 as compared with placebo in a Phase 2 clinical trial support MGL-3196 as a first- and potentially best-in class thyroid hormone receptor...

MDGL : 143.84 (+0.13%)
Madrigal Pharmaceuticals (MDGL) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Madrigal Pharmaceuticals, Inc. (MDGL)

MDGL : 143.84 (+0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More Share

Trade MDGL with:

Business Summary

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia...

See More

Key Turning Points

2nd Resistance Point 146.75
1st Resistance Point 145.30
Last Price 143.84
1st Support Level 142.41
2nd Support Level 140.97

See More

52-Week High 325.98
Fibonacci 61.8% 236.43
Fibonacci 50% 208.77
Fibonacci 38.2% 181.11
Last Price 143.84
52-Week Low 91.56

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar